Xeris Biopharma Holdings, Inc.XERSNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+9.8%
5Y CAGR+19.9%
Year-over-Year Change
Selling, general, and administrative expenses
3Y CAGR
+9.8%/yr
vs +59.8%/yr prior
5Y CAGR
+19.9%/yr
Recent deceleration
Acceleration
-50.0pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.5x
Strong expansion
Streak
9 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $182.37M | +11.6% |
| 2024 | $163.48M | +11.9% |
| 2023 | $146.09M | +6.1% |
| 2022 | $137.75M | +9.6% |
| 2021 | $125.72M | +70.5% |
| 2020 | $73.73M | +16.9% |
| 2019 | $63.06M | +198.7% |
| 2018 | $21.11M | +163.4% |
| 2017 | $8.02M | +97.4% |
| 2016 | $4.06M | - |